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Highly Active Antiretroviral
Therapy: Treatment as
Prevention of HIV/AIDS
The global AIDS pandemic has taken a
major toll worldwide whether it is in terms
of human suffering, lives lost, or economic
impact. At the end of 2009, an estimated
33.3 million people were living with HIV/
AIDS, with a total of 24 million accumu-
lated AIDS-related deaths worldwide and
2.6 million new infections in 2009 alone
[1].
For the first time, in 2010, there has
been a plateau in the growth of the
epidemic [2]. However, the current pro-
tracted global financial crisis is threatening
the sustainability of this achievement, as
the Joint United Nations Programme on
HIV/AIDS (UNAIDS) reported a 10%
drop in funding from 2009 to 2010 as
United States and European governments
reduce funding commitments [2]. Mean-
while, an estimated $US22–23 billion
annually will be needed to fight the HIV
pandemic by 2015, over 40% more than
the US$16 billion allocated in 2010 [3].
This has become particularly worrisome,
as accumulating evidence suggests that the
use of highly active antiretroviral therapy
(HAART) is not just a life-saving strategy
for those infected with HIV, but it is also a
highly effective means of preventing HIV
transmission.
The preventive value of HAART has
now been definitively proven in the
context of serodiscordant couples, where
the immediate use of HAART by the
partner with HIV has led to a relative
reduction of 96% in the number of linked
HIV-1 transmissions, as compared with
delayed therapy in a landmark random-
ized trial [4]. While this result was found
solely in serodiscordant heterosexual cou-
ples, the basic mechanism of HAART
reducing HIV-1-RNA to undetectable
levels in blood, genital secretions, and
breast milk applies to all modes of
transmission. As such, similar protective
benefits have been reported among injec-
tion drug users in Vancouver, British
Columbia, Canada [5], and Baltimore,
Maryland, US [6], as well as population-
based studies [7,8].
Current Evidence on the Cost-
Effectiveness of HAART and HIV
Testing and Prevention
Strategies
HAART has long been deemed to be a
cost-effective intervention, as it is effective
in reducing morbidity and mortality and
increasing life-years and quality-adjusted
life years (QALYs) gained [9]. However,
HAART is associated with substantial up-
front costs, and therefore, there has been
some lingering ambivalence regarding the
expansion of HAART coverage [2]. In-
deed, waiting lists to access HAART
continue to be a recurrent theme in North
America and in resource-limited settings
[10,11]. This is to a large extent based on
an incomplete assessment of the true cost-
effectiveness of HAART roll out, as
illustrated by a recent systematic review.
While 89.7% of studies deemed HAART
to be cost-effective, only 54.2% of the
counseling, testing, and referral strategies
evaluated were found to be cost-effective
by commonly used thresholds in economic
evaluation [12]. Notably, the majority of
these studies focused solely on the patient-
centered benefits of HAART use. As such,
they did not consider the now abundantly
documented secondary benefits of
HAART, chief among them the impact
of HAART on HIV transmission. The
additional return on the investment gen-
erated by decreases in HIV transmission
associated with the use of HAART
markedly enhances the cost-effectiveness
of the overall expanded roll out of
HAART strategy [13]. Consequently, it
is likely that the overall cost-effectiveness
of HAART roll out was significantly
underestimated in the majority of these
studies [4–8]. The evidence is clear:
treatment prevents morbidity, mortality,
and transmission. From this point on, we
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considered together when evaluating the
cost-effectiveness of HAART.
Moving Forward
As we move forward, additional end-
points will need to be captured to fully
understand the economic impact of
HAART expansion. For instance,
HAART is now accepted as a highly
effective means to prevent tuberculosis
[14]. Expanded treatment will also pre-
vent orphanhood, which also carries a
substantial economic burden. One study
found that the annual costs of childcare in
Rwanda and Malawi were equal to or
greater than the annual per capita GDP in
those countries [15]. Finally, HAART will
also have a positive impact on productiv-
ity, particularly in Africa, where AIDS was
conservatively estimated to have reduced
GDP growth rates by 2%–4% per year in
one study [16].
While challenges in implementation of
early detection programs exist [17], par-
ticularly in light of the high risk of
transmission in acute and early HIV
infection [18], the impact of HAART on
HIV transmission has nonetheless pro-
foundly shifted the cost-effectiveness of this
intervention. As a result, the strategic
value of expanded HIV testing and
expansion of HAART coverage has dra-
matically increased. We believe this should
open the door for wide-scale implementa-
tion of ‘‘Seek, Test, Treat and Retain’’
[19] programs as a means to control HIV
and AIDS-related morbidity, mortality,
and transmission at once.
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Summary Points
N In 2010 for the first time there was a plateau in the growth of the AIDS
epidemic, but the current global financial crisis and drop in AIDS funding are
threatening the sustainability of this achievement.
N Growing evidence suggests that HAART is not just life-saving for those with HIV,
but also a highly effective means of preventing HIV transmission. Despite this
evidence, there is lingering ambivalence about the expansion of HAART
coverage.
N In this Essay we argue that the cost-effectiveness of HAART roll out has been
significantly underestimated, as economic analyses have thus far not
considered the secondary benefits of HAART, chief among them the impact
of HAART on HIV transmission.
N We argue that the strategic value of expanded HIV testing and expansion of
HAART coverage has dramatically increased. This has opened the door for the
possibility of wide-scale implementation of ‘‘Seek, Test, Treat and Retain’’
programs as a means to control HIV- and AIDS-related morbidity, mortality, and
transmission at once.
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